CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES ›› 2020, Vol. 38 ›› Issue (1): 53-57.doi: 10.12140/j.issn.1000-7423.2020.01.021

• SHORT COMMUNICATIONS • Previous Articles     Next Articles

Analysis of hospital expenses for patients with end-stage hepatic alveolar echinococcosis receiving ex vivo liver resection and autotransplantation

KASIMU Aihaiti1,2, ABUDUSALAMU Aini1,2, TUERGANAILI Aji1,2,*, SHAO Ying-mei1,3, ZHANG Rui-qing1,2, TALAITI Tuergan1,2, JIANG Tie-min1,2, RAN Bo1,2, ABUDUAINI Abulizi1,2, MIERADILI Aierken4, WEN Hao5   

  1. 1 Department of Hepatobiliary and Hydatid Disease;
    2 Xinjiang Uyghur Autonomous Region Clinical Research Center for Echinococcosis and Hepatobiliary Diseases;
    3 Digestive and Vascular Surgery Center;
    4 Emergency and Trauma Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China;
    5 State Key Laboratory of High Incidence Disease in Central Asia, Xinjiang Medical University, Urumqi 830011, China
  • Received:2019-08-22 Online:2020-02-28 Published:2020-03-19
  • Contact: E-mail: tuergan78@sina.com
  • Supported by:
    Supported by Xinjiang Uyghur Autonomous Region Key Laboratory Open Research Program (No. 2017D04004)

Abstract: We retrospectively collected demographic information as well as relevant clinical data of patients with end-stage hepatic alveolar echinococcosis (AE) treated with ex vivo liver resection and autotransplantation (ELRA) in the First Affiliated Hospital of Xinjiang Medical University during 2010-2018. The patients were divided into six groups based on their medical history prior to ELRA: group A patients having no relevant disease history record; group B having anti-parasitic chemotherapy history; group C having the history of anti-parasitic chemotherapy plus hepatoprotective medication; group D having the record of alleviating jaundice by percutaneous or endoscopic approach plus hepatoprotective medication; group E experienced interventional treatment via liver blood vessel plus anti-parasitic chemotherapy; and group F experienced hepatectomy and anti-parasitic chemotherapy. The medical expenses of different groups were compared by the Mann-Whinty test. A total of 82 patients receiving ELRA were included in this study, with a male/female ratio of 39 : 43 and an average age of (36.12 ± 11.84) years. Most of them were of Zang, Kazakh and Han ethnity, and came from Xinjiang, Tibet and Sichuan. The medical expenses for the hepatic AE patients receiving ELRA treatment included the costs of western medicine, medical examinations, consumable material, ELRA surgery and special material. The average total expense of the 82 patients was (241 155.0 ± 119 746.5) yuan, of which the cost of western medicine accounting the highest proportion (41.1%), followed by the cost of medical examinations (15.7%), consumable material (13.4%), surgery (9.6%) and special material (7.5%). The groups C and D had significantly higher total expenses (P < 0.01) than the other 4 groups. When compared with itemized cost, the group C and D expensed significantly higher for western medicine, medical examinations, nursing, and treatment (P < 0.05), compared with other 4 groups. The group C and D also expensed significantly higher for special material, blood supply, emergency aid, and ward bed than those of group A (P < 0.05). The total and itemized expenses of the patients with no relevant disease history prior to surgery were lower than those with these history records. In addition, occurrence of jaundice or liver dysfunction may increase the total expense and the costs of most items.

Key words: Hepatic alveolar echinococcosis, Ex vivo liver resection and autotransplantation, Hospital cost

CLC Number: